ArticleJHEP reports : innovation in hepatology2026
Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsWeight loss is the cornerstone of treatment for metabolic dysfunction-associated steatotic liver disease (MASLD). This pilot study compared the efficacy and safety of a ketogenic very low energy diet (VLED) vs. a Mediterranean diet (MD) in improving hepatic steatosis and liver histology in individuals with overweight or obesity and MASLD.
methodsWe conducted a pilot randomised controlled trial in adults with histologically confirmed MASLD and a BMI of 27-35 kg/m
resultsThe VLED group (n = 14) achieved significantly greater reduction in MRI-liver-fat-fraction (-77% relative reduction [IQR 51-88]) compared to the MD group (n = 11, -14% [IQR 0-30], p <0.01). The VLED also produced greater TBWL at week 12 (-13% [IQR -17 to -9] vs. -4% [-4.4 to -0.2], p <0.01). At 24 weeks, the VLED/semaglutide group maintained a -14% TBWL (IQR -17 to -10) from baseline vs. -3% TBWL (IQR -4 to 0) in the MD group. Liver histology improved in both groups, with greater improvements in the VLED group (NAFLD activity score reduction VLED: -2 [IQR -3.5 to -2] vs. MD: -1 [IQR -1 to -1], p <0.01).
conclusionsThe ketogenic VLED resulted in significantly greater reduction in hepatic steatosis and weight loss compared to a MD. The very low energy diet is widely available, easily accessible and should be more commonly considered for patients with MASLD and overweight or obesity. IMPACT AND IMPLICATIONS: This pilot randomised controlled trial provides the first direct comparison between a ketogenic very low energy diet (VLED) and a Mediterranean diet (MD) for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), demonstrating greater reductions in hepatic steatosis (77% vs. 14%) and body weight (13% vs. 4%) with the VLED. The growing burden of people who are overweight and obese with early-stage MASLD means that effective dietary weight loss interventions with proven hepatic and metabolic benefits are urgently required. The accessibility, effectiveness, and feasibility of the VLED in clinical settings suggest that it may represent a valuable therapeutic option for selected patients with MASLD and overweight or obesity. CLINICAL
trial registrationwww.anzctr.org.au trial ID: ACTRN12623000756628.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.